Objective: To evaluate interictal, circulating sphingolipids in women migraineurs.Methods: In the fasting state, serum samples were obtained pain-free from 88 women with episodic migraine (EM; n 5 52) and from controls (n 5 36). Sphingolipids were detected and quantified by high-performance liquid chromatography coupled with tandem mass spectrometry using multiple reaction monitoring. Multivariate logistic regression was used to examine the association between serum sphingolipids and EM odds. A recursive partitioning decision tree based on the serum concentrations of 10 sphingolipids was used to determine the presence or absence of EM in a subset of participants.Results: Total ceramide (EM 6,502.9 ng/mL vs controls 10,518.5 ng/mL; p , 0.0001) and dihydroceramide (EM 39.3 ng/mL vs controls 63.1 ng/mL; p , 0.0001) levels were decreased in those with EM as compared with controls. Using multivariate logistic regression, each SD increase in total ceramide (odds ratio [OR] 0.07; 95% confidence interval [CI]: 0.02, 0.22; p , 0.001) and total dihydroceramide (OR 0.05; 95% CI: 0.01, 0.21; p , 0.001) levels was associated with more than 92% reduced odds of migraine. Although crude sphingomyelin levels were not different in EM compared with controls, after adjustments, every SD increase in the sphingomyelin species C18:0 (OR 4.28; 95% CI: 1.87, 9.81; p 5 0.001) and C18:1 (OR 2.93; 95% CI: 1.55, 5.54; p 5 0.001) was associated with an increased odds of migraine. Recursive portioning models correctly classified 14 of 14 randomly selected participants as EM or control.
Conclusion:These results suggest that sphingolipid metabolism is altered in women with EM and that serum sphingolipid panels may have potential to differentiate EM presence or absence.
Classification of evidence:This study provides Class III evidence that serum sphingolipid panels accurately distinguish women with migraine from women without migraine. Neurology ® 2015;85:1214-1223 GLOSSARY BMI 5 body mass index; C1P 5 ceramide-1-phosphate; CI 5 confidence interval; DHC 5 dihydroceramide; DHSM 5 dihydrosphingomyelin; DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition); EM 5 episodic migraine; HIT-6 5 Headache Impact Test-6; LacCer 5 lactosylceramide; MHC 5 monohexosylceramide; OPLS-DA 5 orthogonal partial least squares discriminant analysis; OR 5 odds ratio; PHQ-9 5 Patient Health Questionnaire-9; S1P 5 sphingosine-1-phosphate; SM 5 sphingomyelin.Although the full pathophysiology of migraine is not known, current theories suggest that migraine is largely an inherited brain disorder associated with a sterile, neurogenic inflammation and alterations in neuronal excitability and the cerebrovasculature.1,2 Several lines of evidence also indicate that migraineurs have a greater risk of stroke and disorders related to lipid metabolism including hypercholesterolemia, impaired insulin sensitivity, and obesity. [3][4][5][6] Sphingolipids (e.g., sphingomyelins, ceramides) are a group of bioactive lipids that are critical components of m...